The novel iron-based catalyst exhibits superior performance for ammonia (NH3) synthesis compared to a well-established, century-old counterpart, as reported by researchers at Science Tokyo. By ...
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 484,666 shares of the biopharmaceutical company’s stock ...
However, when you turn failure into a source of potential success instead of fear, it becomes a catalyst for development and ...
Hosted on MSN16h
Greenwich science research class a 'big catalyst' for alumni, now company founders and inventorsRaina Jain said she wouldn't have been able to create her company if it wasn't for the science research class she took in high school. Jain, a 2020 Greenwich High School graduate, took Andy Bramante's ...
Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...
Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...
Researchers in Korea have successfully developed a new material that significantly enhances the efficiency of green hydrogen ...
UC Santa Cruz has announced the Innovation Catalyst Grant proof-of-concept program awardees, showcasing the campus’s ...
Scanning transmission electron microscopy experiments have uncovered the structural changes a ruthenium catalyst undergoes ...
Alloys traditionally consist of two or more metallic elements, with secondary elements enhancing the properties of a primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback